vs
C4 Therapeutics, Inc.（CCCC）与TRANSACT TECHNOLOGIES INC（TACT）财务数据对比。点击上方公司名可切换其他公司
TRANSACT TECHNOLOGIES INC的季度营收约是C4 Therapeutics, Inc.的1.0倍（$11.5M vs $11.0M），C4 Therapeutics, Inc.同比增速更快（112.8% vs 11.9%），过去两年C4 Therapeutics, Inc.的营收复合增速更高（90.4% vs 3.5%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
该公司相关归属主体罗珀技术公司是一家控股集团，主要投资控股科技领域的各类企业，业务覆盖多个科技细分赛道，依托旗下子公司开展多元化科技业务布局。
CCCC vs TACT — 直观对比
营收规模更大
TACT
是对方的1.0倍
$11.0M
营收增速更快
CCCC
高出100.8%
11.9%
两年增速更快
CCCC
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $11.5M |
| 净利润 | $-20.5M | — |
| 毛利率 | — | 47.6% |
| 营业利润率 | -210.1% | -10.1% |
| 净利率 | -186.0% | — |
| 营收同比 | 112.8% | 11.9% |
| 净利润同比 | 40.7% | — |
| 每股收益（稀释后） | $-0.09 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCTACT
| Q4 25 | $11.0M | $11.5M | ||
| Q3 25 | $11.2M | $13.2M | ||
| Q2 25 | $6.5M | $13.8M | ||
| Q1 25 | $7.2M | $13.1M | ||
| Q4 24 | $5.2M | $10.2M | ||
| Q3 24 | $15.4M | $10.9M | ||
| Q2 24 | $12.0M | $11.6M | ||
| Q1 24 | $3.0M | $10.7M |
净利润CCCCTACT
| Q4 25 | $-20.5M | — | ||
| Q3 25 | $-32.2M | $15.0K | ||
| Q2 25 | $-26.0M | $-143.0K | ||
| Q1 25 | $-26.3M | $19.0K | ||
| Q4 24 | $-34.6M | — | ||
| Q3 24 | $-24.7M | $-551.0K | ||
| Q2 24 | $-17.7M | $-319.0K | ||
| Q1 24 | $-28.4M | $-1.0M |
毛利率CCCCTACT
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
营业利润率CCCCTACT
| Q4 25 | -210.1% | -10.1% | ||
| Q3 25 | -306.4% | 0.1% | ||
| Q2 25 | -441.0% | -1.9% | ||
| Q1 25 | -402.9% | -0.1% | ||
| Q4 24 | -728.4% | -10.3% | ||
| Q3 24 | -183.9% | -7.7% | ||
| Q2 24 | -178.6% | -3.8% | ||
| Q1 24 | -1060.2% | -12.2% |
净利率CCCCTACT
| Q4 25 | -186.0% | — | ||
| Q3 25 | -286.4% | 0.1% | ||
| Q2 25 | -402.6% | -1.0% | ||
| Q1 25 | -363.7% | 0.1% | ||
| Q4 24 | -667.8% | — | ||
| Q3 24 | -160.6% | -5.1% | ||
| Q2 24 | -147.6% | -2.8% | ||
| Q1 24 | -933.2% | -9.7% |
每股收益（稀释后）CCCCTACT
| Q4 25 | $-0.09 | $-0.11 | ||
| Q3 25 | $-0.44 | $0.00 | ||
| Q2 25 | $-0.37 | $-0.01 | ||
| Q1 25 | $-0.37 | $0.00 | ||
| Q4 24 | $-0.50 | $-0.80 | ||
| Q3 24 | $-0.35 | $-0.06 | ||
| Q2 24 | $-0.26 | $-0.03 | ||
| Q1 24 | $-0.41 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $20.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.6M | $31.1M |
| 总资产 | $359.1M | $44.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCCCTACT
| Q4 25 | $74.6M | $20.4M | ||
| Q3 25 | $58.8M | $20.0M | ||
| Q2 25 | $78.2M | $17.7M | ||
| Q1 25 | $51.3M | $14.2M | ||
| Q4 24 | $55.5M | $14.4M | ||
| Q3 24 | $59.6M | $11.3M | ||
| Q2 24 | $73.1M | $11.1M | ||
| Q1 24 | $89.7M | $10.6M |
股东权益CCCCTACT
| Q4 25 | $256.6M | $31.1M | ||
| Q3 25 | $154.4M | $31.8M | ||
| Q2 25 | $174.1M | $31.3M | ||
| Q1 25 | $195.1M | $30.9M | ||
| Q4 24 | $216.0M | $30.6M | ||
| Q3 24 | $242.7M | $38.4M | ||
| Q2 24 | $247.1M | $38.5M | ||
| Q1 24 | $258.3M | $38.6M |
总资产CCCCTACT
| Q4 25 | $359.1M | $44.8M | ||
| Q3 25 | $265.5M | $45.0M | ||
| Q2 25 | $296.5M | $44.5M | ||
| Q1 25 | $319.5M | $44.2M | ||
| Q4 24 | $349.6M | $44.0M | ||
| Q3 24 | $376.1M | $50.5M | ||
| Q2 24 | $381.1M | $50.4M | ||
| Q1 24 | $398.4M | $51.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $609.0K |
| 自由现金流经营现金流 - 资本支出 | — | $589.0K |
| 自由现金流率自由现金流/营收 | — | 5.1% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $7.6M |
8季度趋势，按日历期对齐
经营现金流CCCCTACT
| Q4 25 | $-22.1M | $609.0K | ||
| Q3 25 | $-31.2M | $3.6M | ||
| Q2 25 | $-12.1M | $3.6M | ||
| Q1 25 | $-33.3M | $-161.0K | ||
| Q4 24 | $-17.9M | $2.4M | ||
| Q3 24 | $-24.1M | $327.0K | ||
| Q2 24 | $-5.0M | $636.0K | ||
| Q1 24 | $-18.1M | $-1.5M |
自由现金流CCCCTACT
| Q4 25 | — | $589.0K | ||
| Q3 25 | $-31.6M | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | $-17.9M | $2.4M | ||
| Q3 24 | $-24.1M | $259.0K | ||
| Q2 24 | $-5.2M | $499.0K | ||
| Q1 24 | — | $-1.6M |
自由现金流率CCCCTACT
| Q4 25 | — | 5.1% | ||
| Q3 25 | -281.5% | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | -346.5% | 23.2% | ||
| Q3 24 | -157.2% | 2.4% | ||
| Q2 24 | -43.1% | 4.3% | ||
| Q1 24 | — | -14.9% |
资本支出强度CCCCTACT
| Q4 25 | — | 0.2% | ||
| Q3 25 | 3.7% | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 1.6% | 1.2% | ||
| Q1 24 | 0.0% | 1.0% |
现金转化率CCCCTACT
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
